Updated on Jun 30, 2022 | Inside, Research
Left: Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners; and Steven J. Burakoff, MD, Director of The Tisch Cancer Institute at the Icahn School of Medicine
The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and three other leading U.S. academic institutions recently established a pioneering research consortium to accelerate the discovery of new treatments for cancer.
In addition, Celgene Corp., a global biopharmaceutical company, paid $50 million to enter into four public-private collaboration agreements with each member of the new consortium for the option of developing and commercializing novel cancer therapeutics arising from their efforts. (more…)
Updated on Jun 30, 2022 | Research
Kidney transplantation is the most common type of organ transplant surgery in the United States with over 17,000 kidney transplantations performed in 2014, according to the National Kidney Foundation. However, long-term survival still remains a challenge. While there is no actual crystal ball to predict whether a transplanted kidney will later develop fibrosis – a chronic injury that is a major cause of allograft loss after the first year – a team of researchers, led by Mount Sinai’s Barbara Murphy, MD, System Chair, Department of Medicine, Murray M. Rosenberg Professor of Medicine, Dean for Clinical Integration and Population Health, has identified a panel of 13 genes that does just that. These recently discovered 13 genes are highly predictive of decline in renal function and eventual loss of transplanted kidneys. (more…)
Updated on Jun 30, 2022 | Inside, Research
Medical Treatment at Home
An innovative program being run by the Mount Sinai Health System has shown that certain acute-care patients who choose to be treated at home rather than in a hospital are not only more satisfied with their care but also have lower medical costs and fewer medical complications.
These findings come amid the halfway point of a three-year plan that was launched by Mount Sinai in November 2014 after receiving a $9.6 million Health Care Innovation Award from the federal Centers for Medicare and Medicaid Services (CMS) to create a unique “hospital at home” program.
Known as the Mobile Acute Care Team (MACT), the program illustrates Mount Sinai’s commitment to being on the cutting edge of the way medicine will be practiced and creating an innovative health care system for the future, one that emphasizes outpatient, ambulatory, and home-based care with remote monitoring capabilities. The award further highlights Mount Sinai’s role as a pioneer in developing a new clinical and financial reimbursement model for patients with acute illnesses. (more…)
May 21, 2016 | Cardiology, Inside, Research
From left: Rami O. Tadros, MD, FACS; James F. McKinsey, MD, FACS; and Michael L. Marin, MD, FACS, are using a new-generation implantable device to treat complex thoracoabdominal aortic aneurysms.
Physicians at The Mount Sinai Hospital were among the first in the nation to implant an investigational device, a fabric and metal mesh tube known as a stent graft, as part of a clinical trial to treat aneurysms located in the thoracic/abdominal area of the aorta. Mount Sinai is one of only six institutions in the nation granted approval by the U.S. Food and Drug Administration to test the safety and initial feasibility of the device in patients.
The stent graft is used to strengthen the inner lining of the aorta—the main artery that carries blood from the heart to organs—in patients where the aortic walls have weakened and caused a balloon-type bulge known as an aneurysm to grow. Once implanted, the device serves to direct blood flow away from the aneurysm, causing it to shrink in size. If not repaired, the aneurysm can rupture and result in life-threatening internal bleeding. (more…)
May 21, 2016 | Cardiology, Inside, Research
Routine mammograms used for the early detection of breast cancer may also provide women with an early warning of cardiovascular disease, according to a recent study led by Laurie Margolies, MD, Associate Professor of Radiology at the Icahn School of Medicine at Mount Sinai, and Chief of Breast Imaging at the Dubin Breast Center at The Mount Sinai Hospital. (more…)
Updated on Jun 30, 2022 | Research, Your Health
Guest post by Ilana Kersch, MS RD CDN, Senior Dietitian at the Mount Sinai Hospital. Ilana works as part of the inpatient liver transplant team in conjunction with the Recanati Miller Transplant Institute, and provides nutrition care for patients pre- and post-hepatobiliary surgery.
In recent decades, non-alcoholic fatty liver disease (NAFLD) has become an important cause of liver disease in the US due to its association with rising prevalence of obesity and type 2 diabetes. It is estimated that approximately 30% of the US population now has some degree of non-alcoholic fatty liver, and ~2- 5% of the population have fatty liver which has progressed to non-alcoholic steatohepatitis (NASH). If untreated, NAFLD and NASH can progress to liver cirrhosis and malignancy, and is quickly becoming a major indication for listing for liver transplant. (more…)
